Sanofi (SNY) Balance Sheet

The balance sheet appears resilient, with total assets recovering to $128.0B in 2026Q1 from $126.8B in 2025Q4, while equity rose to $72.8B. This stability contrasts with the erratic revenue path, suggesting that asset base is not directly tied to short-term sales performance. The modest increase in assets and equity may reflect retained earnings and disciplined capital management, though the lack of retained earnings data limits deeper analysis.

The debt-to-equity ratio of 0.27 in 2026Q1 is well below peers like AstraZeneca (0.61) and Novartis (0.80), suggesting Sanofi has ample financial flexibility. Total debt has been relatively stable around $20B, with a slight reduction from $21.8B in 2025Q3, which may indicate a strategic approach to debt management rather than necessity-driven borrowing. The low leverage and stable debt levels imply that cash flow durability is not currently threatened by refinancing pressures.

The dramatic increase in goodwill suggests significant acquisition activity, which may be a strategic move to bolster the pipeline. However, this also raises the risk of future impairment if acquired assets underperform. The stable PPE indicates that the company is not heavily investing in fixed assets, consistent with an asset-light model for a pharmaceutical firm. Investors should monitor the composition of this goodwill and the performance of acquired businesses to assess potential write-downs.

The equity base has been stable, but the absence of dividends and buybacks in 2026Q1, as noted in the cash flow analysis, may indicate a strategic shift to conserve cash for acquisitions or debt reduction. This could be a temporary measure, but it also suggests that management is prioritizing balance sheet flexibility over returning capital to shareholders. The lack of retained earnings data makes it difficult to assess the quality of equity, but the stability is a positive sign.

The current ratio approaching 1.0 suggests that current assets barely cover current liabilities, which could strain liquidity if operational cash flows weaken. Cash levels have declined from $15.4B in 2025Q2 to $5.5B in 2026Q1, possibly due to acquisition outflows or debt repayments. While the company still has access to debt markets given its low leverage, the shrinking cash buffer warrants monitoring, especially in light of the volatile earnings seen in 2025Q4.